Ibrutinib+BR a promising treatment option for newly diagnosed MCL ineligible for intensive therapyApril 17, 2023B Cell Lymphoma
Real-world data support the continued use of second-line targeted therapies in CLLApril 17, 2023B Cell Lymphoma
Commentary: Updates on the Treatment of Mantle Cell Lymphoma, April 2023 March 30, 2023B Cell Lymphoma
Standard first‐line chemotherapies for indolent B‐cell lymphoma impose varying risks for a second cancerMarch 23, 2023B Cell Lymphoma
High-dose total body irradiation followed by stem cell transplantation offers long-term survival in MCLMarch 23, 2023B Cell Lymphoma
A complete assessment of TP53 aberrations recommended before initiating ibrutinib in CLLMarch 23, 2023B Cell Lymphoma
Grade 3B FL prognostically similar to grade 3A FL but distinct from DLBCLMarch 23, 2023B Cell Lymphoma
No benefit of adding ibrutinib to chemoimmunotherapy in relapsed/refractory mature B-cell non-Hodgkin lymphomaMarch 23, 2023B Cell Lymphoma
Zanubrutinib elicits favorable long-term responses in relapsed or refractory CLL or SLLMarch 23, 2023B Cell Lymphoma
Chronic lymphocytic leukemia: A risk factor for poor outcomes in patients hospitalized with immune thrombocytopeniaMarch 23, 2023B Cell Lymphoma
Long-term benefits of axicabtagene ciloleucel in refractory large B-cell lymphomaMarch 23, 2023B Cell Lymphoma
Venetoclax may bridge to immunotherapy in relapsed/refractory mantle cell lymphomaMarch 23, 2023B Cell Lymphoma
